Patents by Inventor Feng Wang-Johanning

Feng Wang-Johanning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HERV-K Antibody Therapeutics
    Publication number: 20240059787
    Abstract: The invention provides therapeutic humanized anti-HERV-K antibodies, CAR, or a fusion thereof consisting of a hispecific T ceil engager (BiTE) FOR CD3 and CDS, a DNA-encoded BiTE (DBiTE), or an antibody-drug conjugate (ADC). The invention also relates to peptides, proteins, nucleic acids, and cells for use in immunotherapeutic methods. In particular, the invention relates to the immunotherapy of cancer peptides bound to molecules of the MHC, or peptides as such, which can also be targets of antibodies and other binding molecules.
    Type: Application
    Filed: September 18, 2021
    Publication date: February 22, 2024
    Applicant: SunnyBay Bio Tech, Inc.
    Inventors: Feng Wang-Johanning, Gary Johanning
  • Human application of engineered chimeric antigen receptor (CAR) T-cells
    Patent number: 11786582
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: October 17, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J N Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
  • IDENTIFICATION AND ISOLATION OF ANTIBODIES FROM WHITE BLOOD CELLS
    Publication number: 20190056398
    Abstract: Embodiments in accordance with the present disclosure include apparatuses, devices, and methods. For example, a method is directed to method exposing immobilized white blood cells from a blood sample to an antigen. And, scanning the immobilized white blood cells and, therefrom, identify and isolate white blood cells from among the immobilized white blood cells that produce an antibody in response to the exposure to the antigen.
    Type: Application
    Filed: February 24, 2017
    Publication date: February 21, 2019
    Inventors: Feng Wang-Johanning, Gary L. Johanning, Nathan Collins, Xiaohe Liu, Zheng Ao, Lidia Sambucetti
  • Human application of engineered chimeric antigen receptor (CAR) T-cells
    Patent number: 9629877
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 25, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence JN Cooper, Hiroki Torikai, Ling Zhang, Helen Huls, Feng Wang-Johanning, Lenka Hurton, Simon Olivares, Janani Krishnamurthy
  • HERV-K antigens, antibodies, and methods
    Patent number: 9243055
    Abstract: Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K+ cancers are provided. One example of a method may involve a method for preventing or inhibiting cancer cell proliferation by administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: January 26, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventor: Feng Wang-Johanning
  • ANTI-CANCER VACCINES
    Publication number: 20150250864
    Abstract: The present provides tumor-associated antigens and their use as vaccines for treating and limiting cancers in a patient. In specific aspects, HERV type K envelope proteins and peptides are provided. Such proteins and peptides can be used to elicit specific immune responses—both humoral and cellular—that target tumor cells expressing the HERV type K envelope protein.
    Type: Application
    Filed: June 24, 2013
    Publication date: September 10, 2015
    Applicant: Board of Regents, The University of Texas System
    Inventor: Feng Wang-Johanning
  • HERV-K ANTIGENS, ANTIBODIES, AND METHODS
    Publication number: 20090297530
    Abstract: Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K+ cancers are provided. One example of a method may involve a method for preventing or inhibiting cancer cell proliferation by administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.
    Type: Application
    Filed: May 29, 2009
    Publication date: December 3, 2009
    Inventor: Feng Wang-Johanning
  • HERV-K Antigens, Antibodies, and Methods
    Publication number: 20080019979
    Abstract: Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K+ cancers are provided. One example of a method may involve a method for preventing or inhibiting cancer cell proliferation by administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.
    Type: Application
    Filed: May 22, 2007
    Publication date: January 24, 2008
    Inventor: Feng Wang-Johanning